Wednesday, February 18, 2026 2/18/2026

Spatially resolved, single cell biomarkers of B cell lymphoma

Award Number: R01CA266544
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2022
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Spatially resolved, single cell biomarkers of B cell lymphoma - Project Summary/Abstract Diffuse Large B-Cell Lymphoma (DLBCL) is the most common form of Non-Hodgkin Lymphoma (NHL). DLBCL tumors are highly heterogeneous and molecular profiling has revealed up to six distinct prognostically relevant sub-groups, however these classifications are primarily based on profiles of the malignant cells. Non-malignant cells in the tumor immune microenvironment (TME) can be powerful modulators of tumor growth and can be targeted for cancer therapy, yet biomarkers that include TME elements have not been developed. We hypothesize that successful development of next generation immune targeting therapies for lymphoma will require spatially resolved, highly multiplexed single cell based biomarkers of TME composition and structure. In this study we propose to perform imaging mass cytometry analysis (IMC) on over 2000 cases of aggressive B cell lymphoma with the following aims: Specific Aim 1: Validate spatially-derived protein biomarkers of DLBCL outcomes (n-830 patients). Specific Aim 2: Analyze the single cell topology of histologically diverse aggressive B cell lymphomas (n=1380) to identify shared TME based biomarkers across all aggressive B cell lymphoma. Specific Aim 3: Determine which TME elements modulate chemoresistance and mediate response to immune therapies in lymphoma through in vitro model systems. In the first two Aims, we will apply our novel abundance weighted score (M-score), developed specifically for IMC analysis, to validate candidate biomarkers (such as PD-L1+/CCR4+/TIM-3+) and identify new biomarkers. We will also apply our single cell spatial clustering algorithm, Regions of Immune Cell Organization (RICO), to identify tumor-immune spatial clusters that are associated with clinical outcome. The spatial resolved, single cell, highly multiplexed, digital image analysis proposed here will have clinical impact for the ~80,000 new US cases of NHL. Specific Aim 1 will validate and discover protein biomarkers in a image format familiar to pathologists allowing for seamless clinical adoption, Specific Aim 2 will refine methods for spatial systems biology applied to challenging lymphoma types, and Specific Aim 3 will allow pre-clinical validation of prognostic and predictive biomarkers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $624,093 )
2025	2025	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	4	7/30/2025	NON-COMPETING CONTINUATION	$624,093
														Subtotal = $624,093

Issue Date FY: 2024 ( Subtotal = $886,924 )
2024	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	2	1/30/2024	SUPPLEMENT FOR EXPANSION	$118,869
2024	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	3	8/2/2024	NON-COMPETING CONTINUATION	$768,055
														Subtotal = $886,924

Issue Date FY: 2023 ( Subtotal = $562,886 )
2023	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	2	7/28/2023	NON-COMPETING CONTINUATION	$562,886
														Subtotal = $562,886

Issue Date FY: 2022 ( Subtotal = $616,249 )
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	7/15/2022	NEW	$616,249
														Subtotal = $616,249

Grand Total All Awards = $2,690,152

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Spatially resolved, single cell biomarkers of B cell lymphoma

Award Number: R01CA266544

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2022

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer